Sun Pharma Q4 result: Revenue could see double-digit growth driven by new product launches and strong demand

Pharma major Sun Pharmaceutical will announce its March quarter results on Friday May 22, 2026. Along with the result, the company will also announce a final dividend for its shareholders.

Experts believe Sun Pharma could report 11% to 14% YoY growth in revenue in the range of ₹14,450 to ₹14,800 crore driven by strong performance in domestic and US markets and new product launch in international markets particularly Unloxcyt and Leqselvi. Meanwhile, net profit could also see double digit growth.

The company registered revenues of ₹12,959 crore in Q4FY25 and ₹15,521 crore in the previous quarter. Meanwhile, its net profit stood at ₹3,369 crore in the previous quarter, while its reported net profit of ₹2,150 crore in the same quarter last year.

Investors will look forward to management commentary on speciality product ramp-up, US regulatory developments and final dividend announcement.

Ahead of the Q4 result announcement, Sun Pharma shares closed at ₹1,887, up 0.3% on 21 May. So far this year, Sun Pharma stock has gained nearly 10%.

Technical outlook

Sun Pharma has shown a strong breakout on the weekly chart, moving above the falling trendline resistance near the ₹1,800 to ₹1,820 zone. The stock is currently trading at around ₹1,877 and is holding above its key moving averages, which maintains a positive broader structure.

As long as the stock remains above the recent breakout level ₹1,850, the structure will remain intact. Immediate resistance is located around ₹1,920–₹1,950. Overall, the trend has turned positive, and sustained movement above ₹1,920 could extend the rally.

Options outlook

Sun Pharma’s 26 May expiry options chain shows the at-the-money strike at 1,860 as of 22 May (10am). The combined premium of the ATM call and put stood at around ₹41.

This indicates that the options market is factoring in a possible move of nearly ±2.2% by expiry. To assess whether this move looks reasonable, it is useful to review how Sun Pharma’s stock has typically reacted around its earnings over the past few quarters.

Options strategies

With the options market pricing in a possible move of around ±2.2%, traders can consider volatility-based strategies depending on their view.

A long straddle involves buying the ATM call and put of the same strike and expiry. This strategy may benefit if Sun Pharma moves sharply beyond the expected range in either direction.

On the other hand, a short straddle involves selling the ATM call and put at the same strike and expiry. This strategy works better if the stock remains within the expected ±2.2% range and time decay helps reduce option premiums.

Traders expecting a directional move can also look at spreads. A bull put spread may suit those expecting further upside, while a bear call spread can be considered if the stock breaks down from the current consolidation.

Disclaimer:

Derivatives trading must be done only by traders who fully understand the risks associated with them and strictly apply risk mechanisms like stop losses. The information is only for educational purposes. We do not recommend any particular stock, securities or strategies for trading. The securities mentioned in this article are purely illustrative and not recommendations. Investors are advised to do their own research before investing.